相似文献
1
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.
J Nucl Med. 2010 Feb;51(2):311-28. doi: 10.2967/jnumed.108.058651. Epub 2010 Jan 15.
2
Targeted alpha therapy: part I.
Curr Radiopharm. 2011 Jul;4(3):176. doi: 10.2174/1874471011104030176.
3
Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
Curr Top Med Chem. 2012;12(23):2642-54. doi: 10.2174/1568026611212230002.
4
Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides.
Curr Radiopharm. 2018;11(3):209-214. doi: 10.2174/1874471011666180426130058.
5
Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Radiat Res. 2018 Sep;190(3):236-247. doi: 10.1667/RR15081.1. Epub 2018 Jun 26.
6
Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
Med Phys. 2006 Sep;33(9):3260-9. doi: 10.1118/1.2229428.
7
Alpha-particle microdosimetry.
Curr Radiopharm. 2011 Jul;4(3):266-80. doi: 10.2174/1874471011104030266.
8
The Case for Dosimetry in Alpha-Emitter Therapy.
J Med Imaging Radiat Sci. 2019 Dec;50(4 Suppl 1):S45-S46. doi: 10.1016/j.jmir.2019.07.007. Epub 2019 Sep 16.
9
Targeted and Nontargeted α-Particle Therapies.
Annu Rev Biomed Eng. 2018 Jun 4;20:73-93. doi: 10.1146/annurev-bioeng-062117-120931. Epub 2018 Jan 18.
10
Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis.
Med Phys. 2010 Jun;37(6):2974-84. doi: 10.1118/1.3431999.
引用本文的文献
1
Framework to calculate Ac, Lu, and Tb radiation dose and biological effect in metastatic castration-resistant prostate cancer treatment.
Med Phys. 2025 Aug;52(8):e18035. doi: 10.1002/mp.18035.
2
Impact of intracellular radionuclide distribution in a Monte Carlo biophysical 3D multi-cellular model for targeted alpha therapy.
Med Phys. 2025 Jul;52(7):e17917. doi: 10.1002/mp.17917.
3
Evaluation of relative biological effectiveness of Ac and its decay daughters with Monte Carlo track structure simulations.
EJNMMI Phys. 2025 Jul 7;12(1):65. doi: 10.1186/s40658-025-00765-0.
4
Pb in targeted radionuclide therapy: a review.
EJNMMI Radiopharm Chem. 2025 Jul 1;10(1):34. doi: 10.1186/s41181-025-00362-7.
5
Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy.
Biomimetics (Basel). 2025 Jun 11;10(6):394. doi: 10.3390/biomimetics10060394.
6
Therapeutic evaluation of [Pb]Pb-AB001 and [Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.
Eur J Nucl Med Mol Imaging. 2025 May 21. doi: 10.1007/s00259-025-07330-y.
7
Emerging innovations in theranostics for pancreatic neuroendocrine tumors.
NPJ Precis Oncol. 2025 May 19;9(1):146. doi: 10.1038/s41698-025-00938-1.
8
Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy.
Eur J Nucl Med Mol Imaging. 2025 May 14. doi: 10.1007/s00259-025-07332-w.
9
Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment.
Theranostics. 2025 Mar 31;15(11):4861-4889. doi: 10.7150/thno.106081. eCollection 2025.
10
Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during Lu/Ac treatment in neuroendocrine tumors and metastatic prostate cancer.
Theranostics. 2025 Mar 18;15(10):4368-4397. doi: 10.7150/thno.107963. eCollection 2025.
本文引用的文献
1
MIRD commentary: proposed name for a dosimetry unit applicable to deterministic biological effects--the barendsen (Bd).
J Nucl Med. 2009 Mar;50(3):485-7. doi: 10.2967/jnumed.108.057398.
2
MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature.
J Nucl Med. 2009 Mar;50(3):477-84. doi: 10.2967/jnumed.108.056036.
3
ICRP Publication 105. Radiation protection in medicine.
Ann ICRP. 2007;37(6):1-63. doi: 10.1016/j.icrp.2008.08.001.
4
Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis.
Cancer Biother Radiopharm. 2008 Feb;23(1):74-81. doi: 10.1089/cbr.2007.0408.
5
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
J Nucl Med. 2008 Jan;49(1):30-8. doi: 10.2967/jnumed.107.046938. Epub 2007 Dec 12.
6
Biological response to nonuniform distributions of (210)Po in multicellular clusters.
Radiat Res. 2007 Sep;168(3):332-40. doi: 10.1667/RR0902.1.
7
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
Lancet Oncol. 2007 Jul;8(7):587-94. doi: 10.1016/S1470-2045(07)70147-X.
8
Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
Blood. 2007 Sep 15;110(6):2049-56. doi: 10.1182/blood-2007-01-066803. Epub 2007 May 29.
9
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6250s-6257s. doi: 10.1158/1078-0432.CCR-06-0841.
10
Cancer stem cells and metastasis: lethal seeds.
Clin Cancer Res. 2006 Oct 1;12(19):5606-7. doi: 10.1158/1078-0432.CCR-06-1537.
Zotero 插件